FI950887A0 - MAGE-3-geenistä peräisin oleva ja HLA-A1-proteiinin tarjoama eristetty nonapeptidi ja sen käytöt - Google Patents
MAGE-3-geenistä peräisin oleva ja HLA-A1-proteiinin tarjoama eristetty nonapeptidi ja sen käytötInfo
- Publication number
- FI950887A0 FI950887A0 FI950887A FI950887A FI950887A0 FI 950887 A0 FI950887 A0 FI 950887A0 FI 950887 A FI950887 A FI 950887A FI 950887 A FI950887 A FI 950887A FI 950887 A0 FI950887 A0 FI 950887A0
- Authority
- FI
- Finland
- Prior art keywords
- hla
- presented
- mage
- gene
- derived
- Prior art date
Links
- 108010035452 HLA-A1 Antigen Proteins 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/938,334 US5405940A (en) | 1992-08-31 | 1992-08-31 | Isolated nonapeptides derived from MAGE genes and uses thereof |
US08/037,230 US6235525B1 (en) | 1991-05-23 | 1993-03-26 | Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof |
US08/073,103 US5462871A (en) | 1992-08-31 | 1993-06-07 | Isolated nucleic acid molecules which encode MAGE derived nonapeptides |
PCT/US1993/008157 WO1994005304A1 (en) | 1992-08-31 | 1993-08-30 | Isolated nonapeptide derived from mage-3 gene and presented by hla-a1, and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
FI950887A0 true FI950887A0 (fi) | 1995-02-27 |
FI950887A FI950887A (fi) | 1995-02-27 |
Family
ID=26713936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI950887A FI950887A (fi) | 1992-08-31 | 1995-02-27 | MAGE-3-geenistä peräisin oleva ja HLA-A1-proteiinin tarjoama eristetty nonapeptidi ja sen käytöt |
Country Status (12)
Country | Link |
---|---|
US (2) | US5695994A (de) |
EP (1) | EP0658113B1 (de) |
JP (1) | JP3608788B2 (de) |
AT (2) | ATE280180T1 (de) |
AU (1) | AU668772B2 (de) |
CA (1) | CA2143335C (de) |
DE (1) | DE69333670T2 (de) |
DK (1) | DK0658113T3 (de) |
ES (1) | ES2225824T3 (de) |
FI (1) | FI950887A (de) |
PT (1) | PT658113E (de) |
WO (1) | WO1994005304A1 (de) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7252829B1 (en) | 1998-06-17 | 2007-08-07 | Idm Pharma, Inc. | HLA binding peptides and their uses |
US20020168374A1 (en) * | 1992-08-07 | 2002-11-14 | Ralph T. Kubo | Hla binding peptides and their uses |
US5662907A (en) * | 1992-08-07 | 1997-09-02 | Cytel Corporation | Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes |
US6222012B1 (en) * | 1992-08-31 | 2001-04-24 | Ludwig Institute For Cancer Research | Isolated nonapeptides presented by HLA molecules, and uses thereof |
US5977300A (en) * | 1994-06-03 | 1999-11-02 | Ludwig Institute Of Cancer Research | Isolated nonapeptide which bind to HLA-B44 molecules and the uses thereof |
US6060257A (en) * | 1994-06-03 | 2000-05-09 | Ludwig Institute For Cancer Research | Tumor rejection antigens presented by HLA-B44 molecules, and uses thereof |
US5830753A (en) * | 1994-09-30 | 1998-11-03 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof. |
US5843648A (en) * | 1995-01-10 | 1998-12-01 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods |
US5587289A (en) * | 1995-03-14 | 1996-12-24 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof |
AU705768B2 (en) * | 1995-03-21 | 1999-06-03 | Leiden University | Rage tumor rejection antigens |
CA2224662A1 (en) * | 1995-06-29 | 1997-01-16 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecule which encodes murine tumor rejection antigen precursor smage-3 |
US6951917B1 (en) | 1995-09-26 | 2005-10-04 | The United States Of America As Represented By The Department Of Health And Human Services | MHC-class II restricted melanoma antigens and their use in therapeutic methods |
US7501501B2 (en) | 1995-09-26 | 2009-03-10 | The United States Of America As Represented By The Secretary Department Of Health And Human Services | MHC-Class II restricted melanoma antigens and their use in therapeutic methods |
CO4600681A1 (es) | 1996-02-24 | 1998-05-08 | Boehringer Ingelheim Pharma | Composicion farmaceutica para la modulacion inmunitaria |
US5965535A (en) * | 1997-09-12 | 1999-10-12 | Ludwig Institute For Cancer Research | Mage-3 peptides presented by HLA class II molecules |
EP1584685B1 (de) | 1998-02-05 | 2011-04-13 | GlaxoSmithKline Biologicals SA | Tumorassoziierte Antigenderivate der Mage-Familie, zur Herstellung von Fusionsproteinen mit T-Helper Epitope und Zusammensetzungen zur Impfung |
US7851212B2 (en) | 2000-05-10 | 2010-12-14 | Sanofi Pasteur Limited | Immunogenic polypeptides encoded by MAGE minigenes and uses thereof |
EP1356048A2 (de) | 2000-12-04 | 2003-10-29 | Argonex Pharmaceuticals | Zytotoxisch t-lymphozyte induzierende immunogene zur krebsvorbeugung,behandlung, und diagnose |
WO2002068451A2 (en) * | 2001-02-26 | 2002-09-06 | Albany Medical College | Sperm protein 17 for the diagnosis and treatment of cancer |
JP4541645B2 (ja) | 2001-04-12 | 2010-09-08 | インペリアル・イノベイションズ・リミテッド | I型癌の診断および治療 |
US7892559B2 (en) | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
AU2004280608B2 (en) * | 2002-04-09 | 2012-04-05 | Sanofi Pasteur, Inc. | Modified CEA/B7 vector |
ATE369895T1 (de) | 2002-04-09 | 2007-09-15 | Sanofi Pasteur Ltd | Modifizierte cea nucleinsäure und expressionsvektoren |
CA2510238A1 (en) * | 2002-10-22 | 2004-05-06 | Sanofi Pasteur Limited | Cancer treatment using vaccine and high-dose cytokine |
ES2529203T3 (es) | 2003-01-30 | 2015-02-17 | Survac Aps | Péptidos derivados de survivina y uso de los mismos |
EP1691824B1 (de) | 2003-11-19 | 2009-03-11 | Survac ApS | Proteine der bcl-2-familie und fragmente davon, und ihre verwendung bei krebspatienten |
WO2006113540A2 (en) | 2005-04-14 | 2006-10-26 | Duke University | Use of ntrosylated hemoglobin |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
AR060358A1 (es) | 2006-04-06 | 2008-06-11 | Novartis Vaccines & Diagnostic | Quinazolinas para la inhibicion de pdk 1 |
KR20100093129A (ko) | 2007-12-20 | 2010-08-24 | 노파르티스 아게 | Pi 3 키나제 억제제로서 사용되는 티아졸 유도체 |
US8293753B2 (en) | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
CN102762565A (zh) | 2010-02-22 | 2012-10-31 | 弗·哈夫曼-拉罗切有限公司 | 吡啶并[3,2-d]嘧啶PI3δ抑制剂化合物及使用方法 |
AR082418A1 (es) | 2010-08-02 | 2012-12-05 | Novartis Ag | Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico |
PE20140293A1 (es) | 2011-01-31 | 2014-03-19 | Novartis Ag | Novedosos derivados heterociclicos |
PL2755997T3 (pl) * | 2011-09-15 | 2019-01-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Receptory komórek T rozpoznające MAGE ograniczone do HLA-A1 lub HLA-CW7 |
WO2013061305A1 (en) | 2011-10-28 | 2013-05-02 | Novartis Ag | Novel purine derivatives and their use in the treatment of disease |
GB201120860D0 (en) | 2011-12-05 | 2012-01-18 | Cambridge Entpr Ltd | Cancer immunotherapy |
NZ700924A (en) | 2012-05-16 | 2016-02-26 | Novartis Ag | Dosage regimen for a pi-3 kinase inhibitor |
BR112016011811A2 (pt) | 2013-12-06 | 2017-08-08 | Novartis Ag | Uso de um inibidor de fosfatidilinositol 3-cinase seletivo de alfa-isoforma, regime terapêutico e pacote |
WO2016094309A1 (en) | 2014-12-10 | 2016-06-16 | Myosotis | Inhibition of tnf signaling in cancer immunotherapy |
WO2017009842A2 (en) | 2015-07-16 | 2017-01-19 | Biokine Therapeutics Ltd. | Compositions and methods for treating cancer |
GB201519340D0 (en) | 2015-11-02 | 2015-12-16 | Cambridge Entpr Ltd | Methods of T-lymphocyte expansion |
KR20180073674A (ko) | 2015-11-02 | 2018-07-02 | 노파르티스 아게 | 포스파티딜이노시톨 3-키나제 억제제에 대한 투여 요법 |
GB201519481D0 (en) | 2015-11-04 | 2015-12-16 | Cancer Rec Tech Ltd | Immunomodulatory antibodies |
GB201616238D0 (en) | 2016-09-23 | 2016-11-09 | Adaptimmune Ltd | Modified T cells |
WO2018060833A1 (en) | 2016-09-27 | 2018-04-05 | Novartis Ag | Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib |
DK3565579T3 (da) | 2017-01-05 | 2023-09-04 | Kahr Medical Ltd | Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf |
WO2018127919A1 (en) | 2017-01-05 | 2018-07-12 | Kahr Medical Ltd. | A SIRP1 alpha-41BBL FUSION PROTEIN AND METHODS OF USE THEREOF |
GB201700345D0 (en) | 2017-01-09 | 2017-02-22 | F-Star Beta Ltd | Conditional agonists of immune responses |
IL250916A0 (en) | 2017-03-02 | 2017-06-29 | Geiger Benjamin | Methods for growing t cells in culture and their use |
WO2019006003A1 (en) | 2017-06-27 | 2019-01-03 | The Trustees Of Princeton University | COMPOSITIONS AND METHODS FOR IMPROVING IMMUNOTHERAPY |
GB201713078D0 (en) | 2017-08-15 | 2017-09-27 | Adaptimmune Ltd | T Cell Modification |
CN111836635A (zh) | 2018-01-26 | 2020-10-27 | 剑桥企业有限公司 | 肽交换蛋白 |
MX2021000263A (es) | 2018-07-11 | 2021-05-12 | Kahr Medical Ltd | Proteina de fusion variante sirpalfa-4-1bbl y procedimientos de uso de la misma. |
GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
US20210379109A1 (en) | 2018-08-24 | 2021-12-09 | The Trustees Of Princeton University | Immunotherapy with metabolic enzyme expression |
GB201820444D0 (en) | 2018-12-14 | 2019-01-30 | Adaptimmune Ltd | Marker for T cell expansion |
US20220267409A1 (en) | 2019-07-11 | 2022-08-25 | Kahr Medical Ltd. | Heterodimers and methods of use thereof |
GB201911954D0 (en) | 2019-08-20 | 2019-10-02 | Adaptimmune Ltd | Lentiviral transduction methods |
WO2021137231A1 (en) | 2019-12-31 | 2021-07-08 | Kahr Medical Ltd. | Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same |
WO2021137230A1 (en) | 2019-12-31 | 2021-07-08 | Kahr Medical Ltd. | Methods of culturing t cells and uses of same |
IL276599A (en) | 2020-08-09 | 2022-03-01 | Yeda Res & Dev | T cell receptor unique to mage-a1 and its uses |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4492760A (en) * | 1983-04-19 | 1985-01-08 | The Wistar Institute Of Anatomy And Biology | HLA D Typing assay |
US4707438A (en) * | 1984-08-22 | 1987-11-17 | Tel Aviv University | Immunoassay for breast cancer employing monoclonal antibodies |
JPH03505276A (ja) * | 1988-02-05 | 1991-11-21 | ジェンザイム・コーポレーション | 再配列された組織プラスミノーゲン活性化因子及びその産生方法 |
AU8305491A (en) * | 1990-08-01 | 1992-03-02 | Cytel Corporation | Novel immunosuppressant peptides |
US5342774A (en) | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
IL106610A0 (en) | 1992-08-07 | 1993-12-08 | Cytel Corp | Hla binding peptides and their uses |
US5405940A (en) * | 1992-08-31 | 1995-04-11 | Ludwig Institute For Cancer Research | Isolated nonapeptides derived from MAGE genes and uses thereof |
-
1993
- 1993-08-30 CA CA002143335A patent/CA2143335C/en not_active Expired - Lifetime
- 1993-08-30 JP JP50737394A patent/JP3608788B2/ja not_active Expired - Lifetime
- 1993-08-30 WO PCT/US1993/008157 patent/WO1994005304A1/en active IP Right Grant
- 1993-08-30 AT AT93920419T patent/ATE280180T1/de active
- 1993-08-30 DK DK93920419T patent/DK0658113T3/da active
- 1993-08-30 ES ES93920419T patent/ES2225824T3/es not_active Expired - Lifetime
- 1993-08-30 AT AT03016150T patent/ATE378406T1/de not_active IP Right Cessation
- 1993-08-30 DE DE69333670T patent/DE69333670T2/de not_active Expired - Lifetime
- 1993-08-30 AU AU50969/93A patent/AU668772B2/en not_active Expired
- 1993-08-30 PT PT93920419T patent/PT658113E/pt unknown
- 1993-08-30 EP EP93920419A patent/EP0658113B1/de not_active Expired - Lifetime
-
1995
- 1995-02-27 FI FI950887A patent/FI950887A/fi unknown
- 1995-05-17 US US08/443,341 patent/US5695994A/en not_active Expired - Lifetime
- 1995-05-17 US US08/443,580 patent/US6379901B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ATE280180T1 (de) | 2004-11-15 |
JP3608788B2 (ja) | 2005-01-12 |
US6379901B1 (en) | 2002-04-30 |
PT658113E (pt) | 2005-03-31 |
CA2143335C (en) | 2000-03-14 |
AU5096993A (en) | 1994-03-29 |
JPH08500837A (ja) | 1996-01-30 |
FI950887A (fi) | 1995-02-27 |
WO1994005304A1 (en) | 1994-03-17 |
AU668772B2 (en) | 1996-05-16 |
ATE378406T1 (de) | 2007-11-15 |
EP0658113A4 (de) | 1997-11-26 |
DE69333670D1 (de) | 2004-11-25 |
US5695994A (en) | 1997-12-09 |
ES2225824T3 (es) | 2005-03-16 |
CA2143335A1 (en) | 1994-03-17 |
EP0658113B1 (de) | 2004-10-20 |
EP0658113A1 (de) | 1995-06-21 |
DE69333670T2 (de) | 2005-03-10 |
DK0658113T3 (da) | 2005-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI950887A0 (fi) | MAGE-3-geenistä peräisin oleva ja HLA-A1-proteiinin tarjoama eristetty nonapeptidi ja sen käytöt | |
NO950660L (no) | Isolert nonapeptid avledet fra MAGE-3-gen og presentert ved hjelp av HLA-Al, samt anvendelse derav | |
ATE130029T1 (de) | Hybridome, die monoklonale antikörper gegen neue mucin-epitope produzieren. | |
ATE209680T1 (de) | Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen | |
DE69727966D1 (de) | Ein mit krebs assoziiertes antigen kodierendes isoliertes nukleinsäuremolekül, das antigen selbst, und dessen verwendungen | |
ATE258379T1 (de) | Nukleinsäure, die für einen tumor abstossungsantigenvorläufer kodiert | |
FI963780A (fi) | Kasvainhyljintäantigeeniprekursorista MAGE-2 saatuja eristettyjä peptidejä ja niiden käyttöjä | |
ATE267254T1 (de) | Isolierte peptide, die mit mhc mulekül hla-c-klon 10 komplexe bilden und ihre verwendungen | |
FI954536A0 (fi) | Eristettyjä nukleiinihappomolekyylejä, jotka koodittavat kasvainhyljintäantigeenin esiastetta MAGE-3, ja niiden hyötykäyttö | |
NO934130D0 (no) | Tumoravvisningsantigenforl!pere, tumoravvisningsantigenersamt anvendelse derav | |
DE69511399D1 (de) | Isolierte, von mage-3 abgeleitete peptide, welche mit hla-a2 molekülen komplexieren | |
UY26266A1 (es) | Antigeno asociado con tumores (r11) ley 17164 | |
NZ331398A (en) | Tumor rejection antigens presented by hla-b44 molecules, and uses thereof | |
ATE60574T1 (de) | Hydroxylierte 1,2-diamincyclohexan platinkomplexe. | |
ATE209041T1 (de) | Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendung |